PO.TB10.15 · 肿瘤生物学
聚焦超声开放血脑屏障产生独特的组织特异性细胞外囊泡图谱用于胶质母细胞瘤液体活检
Focused ultrasound BBB opening yields distinct, tissue-specific extracellular vesicle profiles for glioblastoma liquid biopsy
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
引言:细胞外囊泡(EVs)是信息高度密集的液体活检储库,携带反映其亲代细胞实时状态的蛋白质、RNA、脂质和代谢物。在胶质母细胞瘤(GBM)中,EVs为一个原本被隔离的区室提供了独特可及的窗口,然而血脑屏障(BBB)限制了它们在循环中的富集和图谱。使用微泡的聚焦超声(FUS)现已成为一种临床上迅速发展的方法,用于短暂而精确地局部开放BBB,为探究来自肿瘤及周围脑组织的EV通量创造了机会。虽然已证明FUS介导的BBB开放(BBBO)可通过“声活检”增加循环核酸,但其对EV释放和货物的影响仍未充分明确。在此,我们评估FUS-BBBO如何在高保真GBM模型中改变从血浆富集的肿瘤源性与脑源性EVs的丰度和组成。
方法:通过颅内SB28植入建立原位GBM(n=24)。通过对比增强MRI筛查肿瘤,并随机分配到体积匹配的假手术组或FUS治疗组。使用神经导航引导的临床前FUS系统进行BBBO。在治疗后30分钟或24小时采集血浆。通过离子交换色谱分离EVs,并通过NTA和Western印迹进行表征。分别使用Tumor SPARCs™和Neuro SPARCs™富集肿瘤源性和脑源性EVs,并进行DIA-MS蛋白质组学分析。
结果:FUS-BBBO未显著改变与任一区室相关的血浆EV总浓度;相反,它诱导了EV货物的实质性重塑。在所有样本中,共鉴定出>5,000种蛋白质。约80%的差异丰度蛋白质为肿瘤源性或脑源性EV面板所独有,表明对FUS的区室特异性反应。值得注意的是,FUS暴露分别在脑源性和肿瘤源性循环EV群体中产生了222种和290种独特蛋白质。通路分析揭示了在囊泡运输、神经血管应激信号、细胞骨架重塑和免疫调节通路中的富集——可能反映了FUS诱导的肿瘤微环境应激、BBB动态和神经-免疫串扰的改变。
结论:FUS-BBBO在GBM中驱动了强健的、区室特异性的EV蛋白质组重编程,揭示了在假手术条件下不存在的候选生物标志物。这些发现将EV分析定位为一种捕获FUS诱导的组织重塑的敏感方法,并可能扩展可用于空间选择性GBM液体活检的生物标志物库。正在进行的研究正在评估时间动态及其与亲代组织蛋白质组的对应关系。
查看英文原文 English abstract
Introduction: Extracellular vesicles (EVs) are highly information-dense liquid biopsy reservoirs carrying proteins, RNAs, lipids, and metabolites that reflect the real-time state of their parent cells. In glioblastoma (GBM), EVs offer a uniquely accessible window into an otherwise sequestered compartment, yet the blood brain barrier (BBB) restricts their enrichment and profile within the circulation. Focused ultrasound (FUS) with microbubbles is now a clinically burgeoning method for transient and precise local opening of the BBB, creating an opportunity to interrogate EV flux from tumor and surrounding brain. While FUS-mediated BBB opening (BBBO) has been shown to augment circulating nucleic acids via “sonobiopsy,” its effects on EV release and cargo remain poorly defined. Here, we evaluate how FUS-BBBO alters the abundance and composition of tumor- versus brain-derived EVs enriched from blood plasma in a high-fidelity GBM model.
Methods: Orthotopic GBMs were established via intracranial SB28 implantation (n=24). Tumors were screened by contrast-enhanced MRI and randomized into volume-matched sham or FUS treatment groups. BBBO was performed using a neuronavigation-guided preclinical FUS system. Plasma was collected 30 min or 24 h post-treatment. EVs were isolated by ion-exchange chromatography and characterized by NTA and Western blot. Tumor- and brain-derived EVs were enriched using Tumor SPARCs™ and Neuro SPARCs™, respectively, and subjected to DIA-MS proteomic analysis.
Results: FUS-BBBO did not significantly alter total plasma EV concentrations associated with either compartment; rather, it induced substantial remodeling of EV cargo. Across samples, >5,000 proteins were identified. Approximately 80% of differentially abundant proteins were unique to either the tumor- or brain-derived EV panel, indicating compartment-specific responses to FUS. Strikingly, FUS exposure yielded 222 and 290 unique proteins within brain-derived and tumor-derived circulating EV populations, respectively. Pathway analysis revealed enrichment in vesicle trafficking, neurovascular stress signaling, cytoskeletal remodeling, and immune regulatory pathways - potentially reflecting FUS-induced alterations in tumor microenvironmental stress, BBB dynamics, and neuro-immune cross-talk.
Conclusions: FUS-BBBO drives robust, compartment-specific reprogramming of EV proteomes in GBM, revealing biomarker candidates absent under sham conditions. These findings position EV profiling as a sensitive approach for capturing FUS-induced tissue remodeling and may expand the biomarker repertoire available for spatially selective GBM liquid biopsy. Ongoing studies are assessing temporal dynamics and correspondence with parental tissue proteomes.
利益披露 Disclosure
A. Thede, None..
Z. Demir, None..
K. Imomnazarov, None..
S. Maslova, None..
R. Short-Miller, None..
S. Lodmell, None..
K. VanVaerenberghe, None..
C. Seibold, None..
A. LaBonte, None..
K. Havranek, None..
N. D. Sheybani, None.